<table border="1" cellpadding="0" cellspacing="0" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="131.4pt"></col>
<col width="419.4pt"></col>
<tbody>
<tr>
<td colspan="2" stylecode="     Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Table 6: Clinically Significant Drug Interactions with Paricalcitol </content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">CYP3A Inhibitors </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Paricalcitol is partially metabolized by CYP3A. Hence, exposure of paricalcitol will increase upon co-administration with strong CYP3A inhibitors such as but not limited to: boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention </content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Dose adjustment of paricalcitol capsules may be necessary. Monitor closely for iPTH and serum calcium concentrations, if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Cholestyramine</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact </content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of paricalcitol. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention </content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Recommend to take paricalcitol capsules at least 1 hour <content stylecode="underline">before</content> or 4 to 6 hours <content stylecode="underline">after</content> taking cholestyramine (or at as great an interval as possible) to avoid impeding absorption of paricalcitol. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Mineral Oil</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact </content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Mineral oil or other substances that may affect absorption of fat may influence the absorption of paricalcitol. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention </content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Recommend to take paricalcitol capsules at least 1 hour <content stylecode="underline">before</content> or 4 to 6 hours <content stylecode="underline">after</content> taking mineral oil (or at as great an interval as possible) to avoid affecting absorption of paricalcitol. </paragraph>
</td>
</tr>
</tbody>
</table>